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Aims: To investigate the relationship between heart rate and outcomes in heart failure and 2 
reduced ejection fraction (HFrEF) patients in sinus rhythm (SR) and atrial fibrillation (AF) 3 
adjusting for natriuretic peptide concentration, a powerful prognosticator.  4 
 5 
Methods and Results: Of 13,562 patients from two large HFrEF trials, 10,113 (74.6%) were 6 
in SR and 3449 (25.4%) in AF. The primary endpoint was the composite of cardiovascular 7 
death or HF hospitalization. Heart rate was analysed as a categorical (tertiles, T1-3) and 8 
continuous variable (per 10-beats per minute [bpm]), separately in patients in SR and AF. 9 
Outcomes were adjusted for prognostic variables, including N-terminal prohormone of B-10 
type natriuretic peptide (NT-proBNP), and also examined using change from baseline heart 11 
rate to one year (≤-10-bpm, ≥+10-bpm, <±10-bpm).  12 
 13 
SR patients with a higher heart rate had worse symptoms and quality of life, more often had 14 
diabetes and higher NT-proBNP concentrations. They had higher risk of the primary endpoint 15 
(T3 vs. T1 adjusted-hazard ratio [HR] 1.50; 95% confidence interval [CI] 1.35–1.66; 16 
p<0.001; per 10-bpm 1.12, 1.09-1.16; p<0.001). In SR, heart rate was associated with a 17 
relatively higher risk of pump failure than sudden death: adjusted-HR per 10-bpm 1.17 (1.09-18 
1.26; p<0.001) vs. 1.07 (1.02-1.13; p=0.011), respectively. Heart rate was not predictive of 19 
any outcome in AF. 20 
 21 
Conclusions: In HFrEF, an elevated heart rate was an independent predictor of adverse 22 
cardiovascular outcomes in patients in SR, even after adjustment for NT-proBNP. There was 23 
no relationship between heart rate and outcomes in AF. 24 
 25 
 5 
Word count: 243 26 
Clinical Trial Registration— 27 
URL: http://www.clinicaltrials.gov. Unique identifiers: NCT01035255 & NCT00853658  28 
 6 
INTRODUCTION 29 
In heart failure with reduced ejection fraction (HFrEF) elevated resting heart rate is 30 
associated with higher morbidity and mortality in patients in sinus rhythm.1–5 Furthermore, in 31 
these patients, heart rate has been demonstrated to be a modifiable risk factor using 32 
ivabradine, an inhibitor of the sinus node If current which has the sole pharmacological effect 33 
of lowering heart rate.6 However, some questions remain regarding the relationship between 34 
heart rate and outcomes in HFrEF patients in sinus rhythm. Existing analyses did not adjust 35 
for natriuretic peptide concentration, which is the single most powerful predictor of outcome 36 
in HF and natriuretic peptide levels are higher in patients with a higher heart rate.7 The prior 37 
studies were also too small to examine the relationship between heart rate and the major 38 
modes of death in HFrEF i.e. sudden death and death due to worsening HF. Finally, little is 39 
known about how change in heart rate relates to outcomes. 40 
 41 
The relationship between heart rate and outcomes for HFrEF patients in atrial fibrillation 42 
(AF) is not as well studied or as clear-cut. AF is frequent in HFrEF and becomes more 43 
common as HF severity worsens.8 Although several post-hoc analyses of trial and 44 
observational cohorts have reported no relationship between heart rate and outcomes in 45 
HFrEF and AF, these studies have a number of limitations.3,5,9–13 For example, not all 46 
differentiated between history of AF and AF documented on an ECG at time of enrolment. 47 
This is relevant for a number of reasons, including the recent finding that only paroxysmal 48 
and new-onset AF, but not permanent or persistent AF, are associated with worse outcomes 49 
in patients with HFrEF.14 More importantly, none of these prior studies included routine 50 
measurement of  natriuretic peptides, which are elevated further in patients with AF, 51 
compared to those in sinus rhythm.15 Existing studies cannot, therefore, reliably tell whether 52 
resting ventricular rate is an independent predictor of adverse cardiovascular outcomes in 53 
 7 
patients with HFrEF and AF. Neither can these studies provide a like-with-like comparison of 54 
the relationship between ventricular rate and outcomes in patients in AF and sinus rhythm, 55 
which needs to take account of differing levels of natriuretic peptides in these two groups. As 56 
in patients in sinus rhythm, little is known about how change in heart rate relates to 57 
outcomes. 58 
 59 
We therefore examined the association between baseline resting ventricular rate (hereafter 60 
referred to as “heart rate”) and outcomes in two large, international, multicentre, 61 
contemporary, randomized clinical trials in patients with HFrEF using rhythm determined by 62 
a baseline ECG and adjusting for N-terminal prohormone of B-type natriuretic peptide (NT-63 

















Study population and procedures 80 
The design, baseline characteristics and results of the Prospective comparison of ARNI with 81 
ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure 82 
(PARADIGM-HF) and Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure 83 
(ATMOSPHERE) trials have been published in detail previously.16–21 Both trials were 84 
approved by the ethics committee at each study centre and all patients provided written 85 
informed consent. 86 
 87 
The inclusion criteria for PARADIGM-HF and ATMOSPHERE were broadly similar. In 88 
brief, patients were eligible for inclusion if they were ≥18 years of age, were New York Heart 89 
Association (NYHA) functional class II to IV, had a left ventricular ejection fraction (LVEF) 90 
≤35% (changed from ≤40% initially in the PARADIGM-HF trial by amendment) and had 91 
elevated natriuretic peptide levels (cut-off was independent of the presence or not of atrial 92 
fibrillation). Prior to screening, treatment with an angiotensin-converting enzyme inhibitor or 93 
angiotensin receptor blocker at a dose equivalent to enalapril 10 mg daily for at least 4 weeks 94 
was mandatory, along with a beta-blocker (unless contraindicated or not tolerated) and a 95 
mineralocorticoid receptor antagonist, if indicated. Exclusion criteria at screening included 96 
symptomatic hypotension or systolic blood pressure <95 mm Hg (<90 mm Hg in the 97 
ATMOSPHERE trial), estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2 (<35 98 
ml/min/1.73 m2 in the ATMOSPHERE trial), and potassium >5.4 mmol/l (>5.2 mmol/l in the 99 
ATMOSPHERE trial). 100 
 101 
Both trials involved a sequential run-in period where baseline therapy with an angiotensin-102 
converting enzyme inhibitor or angiotensin receptor blocker was stopped and patients first 103 
 9 
received enalapril followed by sacubitril/valsartan in the PARADIGM-HF trial and enalapril 104 
followed by the combination of enalapril plus aliskiren in the ATMOSPHERE trial. Patients 105 
who tolerated the target doses of the drugs were then randomly assigned to double-blind 106 
therapy with sacubitril/valsartan 97/103mg BID or enalapril 10mg BID in a 1:1 ratio in the 107 
PARADIGM-HF trial or enalapril 10mg BID, aliskiren 150mg OD (increased to 300mg OD 108 
after two weeks if tolerated), or both drugs in a 1:1:1 ratio in the ATMOSPHERE trial.  109 
 110 
In the two trials, investigators were asked to report on the heart rhythm from the baseline 111 
electrocardiograph (ECG) along with the ECG recorded heart rate. For the purposes of this 112 
analysis, the small number of patients with atrial flutter are included along with those patients 113 
with AF on their baseline ECG. Patients who were recorded as having a paced rhythm on 114 
their baseline ECG were excluded from this analysis.  115 
 116 
Outcomes 117 
The primary outcome of both trials was a composite of time to first occurrence of 118 
cardiovascular (CV) death or HF hospitalization. In this analysis, we investigated the 119 
association between baseline heart rate and the risk of the primary outcome, each of its 120 
components, sudden death, pump failure death and death from any cause. We performed 121 
these analyses separately in those patients with sinus rhythm and those with AF on baseline 122 
ECG. All endpoints were adjudicated by the same clinical endpoint committee according to 123 
prespecified criteria. 124 
 125 
Statistical analysis 126 
Baseline characteristics are presented by groups defined by heart rate tertile (calculated 127 
separately for AF and sinus rhythm), with mean ± standard deviation or median (interquartile 128 
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range) for continuous variables and frequency and percentage for categorical variables. 129 
Differences in baseline characteristics according to heart rate tertile from baseline ECG 130 
recorded heart rate distribution were assessed with a test for trend by means of variance 131 
weighted least square regression for continuous variables and with a nonparametric test for 132 
trend for categorical variables.22 Differences in baseline characteristics according to baseline 133 
heart rhythm were assessed using the chi-square test for categorical variables and analysis of 134 
variance (ANOVA) or Kruskal–Wallis test for continuous variables.  135 
 136 
Incidence rates for the outcomes are presented per 100 person-years. Time to event curves are 137 
presented by tertiles of baseline ECG recorded heart rate, estimated using the Kaplan-Meier 138 
method and compared using the log-rank test. Cumulative incidence functions for the 139 
endpoints of interest were calculated accounting for the competing risks of all-cause death 140 
and non-CV death. No significant differences were observed, therefore Kaplan-Meier 141 
estimates are presented. Hazard ratios (HRs) with 95% confidence intervals (CIs) of 142 
outcomes according to heart rate tertiles were calculated using Cox proportional hazard 143 
models using tertile 1 as the referent. A sensitivity analysis was performed using the 144 
calculated sinus rhythm heart rate tertiles in those patients in AF on baseline ECG. 145 
Heart rate was also modelled as a continuous variable with hazard ratios and 95% CIs 146 
presented for 10 beats per minute (bpm) increments. This relationship is presented 147 
graphically in a linear model with the hazard ratios relative to a baseline heart rate of 80bpm 148 
(chosen on the basis of the Rate Control Efficacy in Permanent Atrial Fibrillation: a 149 
Comparison between Lenient versus Strict Rate Control II [RACE II] trial).23 The presence of 150 
any interaction between heart rate and rhythm on outcomes was tested. 151 
 152 
 11 
Models were adjusted for randomized treatment (enalapril, sacubitril/valsartan, aliskiren, or 153 
combination of enalapril and aliskiren), and the following baseline characteristics: age, sex, 154 
race, geographical region, NYHA functional class, LVEF, systolic blood pressure, body mass 155 
index, eGFR, duration of HF, history of HF hospitalization, history of myocardial infarction, 156 
history of diabetes, history of stroke, treatment with digoxin, treatment with beta-blockers, 157 
treatment with amiodarone and log NT pro-BNP. Data for NT-proBNP at baseline was 158 
missing in 12 and 593 patients in the analysis from PARADIGM-HF and ATMOSPHERE 159 
respectively. For the 593 patients in ATMOSPHERE, imputed values were used as calculated 160 
for the original primary trial analysis and detailed in the trial protocol.21,24 The proportional 161 
hazards assumption was examined using log (-log(survival)) curves and was found to valid 162 
for all models. A sensitivity analysis was performed for the primary composite outcome and 163 
the outcome of sudden cardiac death with the addition of covariates indicating treatment with 164 
mineralocorticoid receptor antagonists and the use of implantable cardioverter defibrillators 165 
and/or cardiac resynchronisation therapy to the adjusted Cox models. The addition of these 166 
covariates did not significantly alter the results presented (data not shown). A further 167 
sensitivity analysis including patients with a paced rhythm on baseline ECG who had a 168 
cardiac resynchronisation therapy device did also not significantly influence the results (data 169 
not shown).  170 
 171 
The association between change in heart rate over time and outcomes was explored for 172 
patients who had ECGs at both baseline and 12-months and who remained in the same 173 
rhythm as their baseline ECG. Three groups were identified; those whose heart rate increased 174 
by 10 bpm or more, those whose heart rate decreased by 10 bpm or more and those whose 175 
heart rate increased or decreased by less than 10 bpm. Outcomes were analysed using Cox 176 
proportional hazard models for events occurring at least 12 months following randomization 177 
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and adjusted for the same baseline characteristics as detailed above and baseline heart rate, 178 
with the referent group being those with a less than 10 bpm change in ECG recorded heart 179 
rate over 12 months. The proportion of patients reporting a clinically meaningful change in 180 
KCCQ clinical summary score (5 or more points) and mean difference in NT-pro BNP (only 181 
available for patients enrolled in ATMOSPHERE) at 12 months were calculated and 182 
compared between the three groups using the same statistical methods as for baseline 183 
characteristics detailed above. 184 
All P-values are two-sided and a P-value of <0.05 was considered significant. Analyses were 185 



















Of the 15,145 patients randomized in both trials, 1715 (11.1%) patients were reported to have 204 
a paced ECG rhythm and were excluded from this analysis (Supplemental Figure 1). An 205 
additional 138 (0.9%) had either no baseline ECG recorded or missing heart rate data. 13,562 206 
patients remained, of which 3449 (25.4%) and 10,113 (74.6%) were reported as having a 207 
baseline ECG rhythm of AF and sinus rhythm, respectively.  208 
 209 
Baseline characteristics 210 
The distribution of ECG recorded baseline heart rate for patients in sinus rhythm and those in 211 
AF is displayed in Supplemental Figure 2. The mean heart rate was higher in patients with 212 
AF (79.9 bpm ± 17.2) compared to those in sinus rhythm (70.1 bpm ± 13.1; p<0.001). 213 
Tertiles for baseline heart in AF were calculated as follows: tertile 1 (T1) ≤72 bpm, tertile 2 214 
(T2) 73-85 bpm, and tertile 3 (T3) ≥86 bpm. The corresponding rates for patients in sinus 215 
rhythm were:  ≤63 bpm, 64-75 bpm and ≥76 bpm. 216 
 217 
Baseline characteristics are summarised in Supplemental Table 1 according to heart rate 218 
tertiles and baseline ECG heart rhythm. The differences between those with sinus rhythm or 219 
AF at baseline are summarised in Supplemental Table 2. Irrespective of heart rhythm, 220 
patients with a lower heart rate were more commonly male, older, had a lower eGFR, 221 
reported less severe NYHA functional class symptoms, had a longer duration of HF, were 222 
less likely to have been hospitalised for HF and more often had an ischaemic aetiology. 223 
Treatment with digoxin was less common in the lowest tertile of heart rate but amiodarone 224 
was used more commonly, and these patients were more likely to have an implantable 225 
cardioverter defibrillator (ICD). The use of diuretics was more common in the highest tertile 226 
of heart rate in patients with sinus rhythm whereas no significant difference between tertiles 227 
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was seen in AF. In sinus rhythm but not AF, beta-blocker use was highest in the lowest heart 228 
rate tertile (T1 vs. T3 93.9% vs 89.0%, p<0.001). Lower baseline heart rate was associated 229 
with a higher LVEF in sinus rhythm but not in AF.  230 
 231 
N-terminal prohormone of B-type natriuretic peptide 232 
NT-proBNP concentration increased from the lowest to highest tertile of heart rate in patients 233 
with sinus rhythm (p<0.001), whereas in AF there was a trend to lower levels of NT-proBNP 234 
with a higher heart rate, but this did not reach statistical significance (p=0.06).  235 
 236 
Kansas City Cardiomyopathy Questionnaire  237 
In both AF and sinus rhythm, a lower heart rate was associated with a higher (better) Kansas 238 
City Cardiomyopathy Questionnaire (KCCQ) score (p<0.001 in both). 239 
 240 
Clinical outcomes according to heart rate tertile 241 
Sinus rhythm 242 
 The risk of all outcomes was significantly higher in patients with a higher heart rate on their 243 
baseline ECG (Figure 1 and Supplemental table 3). This elevated risk remained significant 244 
for all outcomes after adjustment for other prognostic variables (Figure 2 and Supplemental 245 
table 3). The greatest relative risk was observed for pump failure death where there was a 246 
70% greater risk of this mode of death in those in the highest heart rate tertile compared to 247 
the lowest (adjusted hazard ratio [HR] 1.70; 95% confidence interval [CI] 1.30-2.22; 248 
p<0.001). The corresponding adjusted HR for sudden death was 1.28; 95%CI 1.06-1.54; 249 
p=0.011. 250 
 251 
Atrial fibrillation 252 
 15 
In patients with AF on their baseline ECG, only the risk of pump failure death differed 253 
according to heart rate, with a lower risk in the upper two heart rate tertiles compared to the 254 
lowest tertile (T2 unadjusted HR 0.67; 95% CI 0.47-0.97; p=0.035 and T3 unadjusted HR 255 
0.67; 95% CI 0.46-0.96; p=0.031). However, this risk was not significant after adjustment for 256 
prognostic variables (Figure 2 and Supplemental table 3). The risk of all other outcomes was 257 
not significantly different between tertiles of heart rate (Figures 1, 2 and Supplemental table 258 
3). Similar results were found in a sensitivity analysis for patients with AF at baseline using 259 
the sinus rhythm tertile heart rate ranges (Supplemental Table 4). 260 
 261 
Clinical outcomes using heart rate as a continuous variable 262 
Sinus rhythm 263 
When modelled as a continuous variable, a 10 bpm increase in baseline heart rate was 264 
associated with a significantly higher risk of all outcomes for patients in sinus rhythm, even 265 
after adjustment for other prognostic variables (Table 1). This ranged from a 7% higher risk 266 
of sudden death (adjusted HR 1.07; 95% CI 1.02-1.13; p=0.011) to a 17% higher risk of 267 
pump failure death (adjusted HR 1.17; 95% CI 1.09-1.26; p<0.001). The risk of HF 268 
hospitalization was 13% higher per 10 bpm increase in heart rate (adjusted HR 1.13; 95% CI 269 
1.09-1.18; p<0.001). The risk of each of cardiovascular and all-cause mortality was also 270 
significantly higher per 10 bpm increase - by 11% and 12%, respectively, after adjustment for 271 
prognostic variables. 272 
 273 
Atrial fibrillation 274 
In AF, there was no association between a 10 bpm increase in baseline heart rate and any of 275 
the outcomes of interest after adjustment for other prognostic variables (Table 1). There was 276 
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a significant interaction for all outcomes between baseline heart rhythm (sinus rhythm or AF) 277 
and baseline heart rate as a continuous variable (Table 1). 278 
 279 
Relationship between change in heart rate at 12 months following randomization and 280 
outcomes 281 
Data on heart rate and rhythm recorded on ECG at 12 months were available for 10260 282 
patients (75.7%) who remained in the same rhythm as on baseline ECG. Of these, 7756 283 
(75.6%) were in sinus rhythm and 2504 (24.4%) in AF. 284 
 285 
Sinus rhythm 286 
Mean heart rate at twelve months in patients in sinus rhythm was 0.7 bpm higher than at 287 
baseline (70.0 bpm vs. 69.3 bpm, p<0.001). For most patients in sinus rhythm (4943 288 
[63.7%]), heart rate differed by less than 10 bpm from baseline. Heart rate was lower than 289 
baseline by at least 10 bpm in 1274 patients (16.4%) and higher by 10 bpm or more in 1539 290 
(19.8%).  291 
 292 
The associations between change in heart rate and outcomes occurring after 12 months of 293 
follow-up are reported in Table 2. In sinus rhythm, the risk of all outcomes examined, except 294 
sudden cardiac death, was significantly higher in those with an increase in heart rate of 10 295 
bpm or more, compared to those whose rate increased by less than 10 bpm or decreased. A 296 
lower risk of the primary composite endpoint (and HF hospitalization) was observed in those 297 
with a HR decrease of at least 10 bpm by 12 months of follow-up. All other endpoints 298 
showed similar trends, but these were not statistically significant.  299 
 300 
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An increase in heart rate of 10bpm or more at 12 months in patients in sinus rhythm was 301 
associated with a mean increase of NT-pro BNP of 424 pg/ml (SD 2754), whereas a decrease 302 
in heart rate of 10bpm or more was associated with a fall of 414 pg/ml (SD 2271), p for trend 303 
<0.001 (Table 3). A greater proportion of patients with a reduction in heart rate of at least 10 304 
bpm reported a clinically meaningful increase in the KCCQ clinical summary score at twelve 305 
months. Conversely, a greater proportion of patients with an increase in heart rate of 10 bpm 306 
or more reported a reduction in the KCCQ clinical summary score of at least 5 points (p for 307 
trend <0.001). 308 
 309 
Atrial fibrillation 310 
In patients with AF, baseline heart rate was 79.9 bpm and 80.5 bpm at 12 months (p=0.05).   311 
In patients with AF at 12 months, 1217 (48.6%) had a difference of less than 10 bpm, 611 312 
(24.4%) had a lower heart rate (at least 10 bpm lower) and 676 (27.0%) had an increase of at 313 
least 10 bpm. Similar trends were seen for a higher risk in those experiencing an increase in 314 
heart rate and a lower risk associated with a reduction in heart rate, although only some of 315 
these were statistically significant: an increase in heart rate was associated with a higher risk 316 
of the composite primary endpoint, HF hospitalization and pump failure death; a reduction in 317 
heart rate and a lower risk of all-cause mortality. 318 
 319 
The changes in NT-pro BNP levels and KCCQ clinical summary score associated with 320 
changes in heart at 12 months seen in patients with AF were similar to those described above 321 






This analysis from the PARADIGM-HF and ATMOSPHERE trials is to our knowledge, the 327 
first to describe the relationship between baseline heart rate and cardiovascular outcomes in 328 
patients with chronic, ambulatory, HFrEF in both sinus rhythm and AF, where risk was 329 
adjusted for natriuretic peptide levels. Additional unique features of our study are that we had 330 
an assessment of health-related quality of life in all participants at baseline and that our 331 
dataset was large enough to examine both major modes of death in patients with HFrEF i.e. 332 
sudden death and death due to pump failure.  333 
 334 
Although many adverse prognostic findings were more common at baseline in patients in 335 
sinus rhythm with higher heart rates, heart rate remained a predictor of outcome after 336 
adjustment for these differences. We also observed that higher heart rate was associated with 337 
higher natriuretic peptide concentration in these individuals. However, the prognostic 338 
importance of an elevated heart rate persisted even after additional adjustment for natriuretic 339 
peptide levels, confirming that heart rate is a robust, independent, marker of adverse 340 
outcomes in HFrEF patients in sinus rhythm.  341 
 342 
Another important finding was that, in patients in sinus rhythm, an elevated heart rate was 343 
associated with a relatively higher risk of death from progressive pump failure than with 344 
sudden death, although the risk of both modes of death was higher in patients with a higher 345 
heart rate (adjusted hazard ratio per 10 bpm increase in heart rate:  1.17 [95% CI 1.09-1.26] 346 
vs. 1.07 [1.02-1.13]). This relatively stronger association between heart rate and pump 347 
failure, compared with sudden death was also seen in our analysis of change in heart rate. It is 348 
of interest, therefore, that in the Systolic Heart failure treatment with the If inhibitor 349 
ivabradine Trial (SHIFT), pump failure death was reduced significantly by ivabradine (HR 350 
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0·74; 95% CI 0·58–0·94, p=0·014)  whereas sudden death was not (HR 1.05; 95% CI 0·87–351 
1.26, p=0·63).6 Collectively, these findings suggest that the purported beneficial effects of a 352 
lower heart rate, including myocardial energy conservation, improved coronary blood flow 353 
secondary to diastolic prolongation, as well as an improvement in the positive force–354 
frequency relationship (Bowditch effect), have more impact on worsening pump function.25,26 355 
These findings also point to an additional effect of beta-blockers beyond heart rate lowering, 356 
as beta-blockers also lead to a substantial reduction in sudden death.  This suggests that 357 
increased adrenergic activity increases the risk of ventricular arrhythmias independently of 358 
increasing heart rate and that reduction in sudden death is a non-heart rate-related benefit 359 
from beta-blockade.  360 
 361 
Our findings related to heart failure hospitalization (lower risk in patients with a lower heart 362 
rate) and quality of life (better KCCQ clinical summary score in patients with a lower heart 363 
rate) are also consistent with the benefits of heart rate reduction in HFrEF patients in sinus 364 
rhythm demonstrated in SHIFT.27 The findings of our analysis of change in heart rate were 365 
also consistent with SHIFT and a post-hoc analysis of the CHARM (candesartan in heart 366 
failure: assessment of reduction in mortality and morbidity) program.2,6,28 Specifically, in 367 
SHIFT, a mean overall placebo-corrected reduction in heart rate of 9.1 bpm with ivabradine 368 
at 1 year was associated with a 18% reduction in risk of the primary composite endpoint; in 369 
our analysis a decrease in HR of 10 bpm at 1 year was associated with a 26% lower risk of 370 
the same outcome. In the placebo group in SHIFT, a 5 bpm increase in heart rate was 371 
associated with a 16% higher risk of the primary composite outcome and in our study a 10 372 
bpm increase was associated with a 52% higher risk.2 Furthermore, our observation that a 373 
reduction in heart rate was associated with a greater proportion of patients reporting 374 
improvements in quality of life, as measured by KCCQ clinical summary score, is similar to 375 
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that observed in SHIFT.27 Additionally, we report that a decrease in heart rate was 376 
accompanied by a reduction in NT-pro BNP levels. 377 
 378 
In contrast to what we observed in patients in sinus rhythm, ventricular rate was of no 379 
prognostic import in those with AF on their baseline ECG. It has been suggested that this 380 
discrepancy may be explained by any benefit of heart rate reduction in AF being offset by an 381 
increase in risk related to the use of heart rate lowering drugs in these patients. The two 382 
principal concerns are that such treatments may aggravate atrioventricular conduction disease 383 
and worsen haemodynamic status in patients reliant on a higher ventricular rate to maintain 384 
cardiac output in the face of loss of the “atrial-kick”.29 On the other hand, we found that 385 
quality of life (as measured by the KCCQ clinical summary score) was better in patients with 386 
a lower ventricular rate and this finding was supported by examination of NYHA functional 387 
class. Moreover, we found that an increase in ventricular rate over time in patients with AF 388 
was associated with worse outcomes as previously reported in an analysis of the CHARM 389 
programme.28 An increase in ventricular rate was accompanied by an increase in NT-pro 390 
BNP level and a deterioration in quality of life. This suggests that the relationship between 391 
ventricular rate and health status in HFrEF patients with AF is more complex than perhaps 392 
previously appreciated. It is even possible that achieving the optimum ventricular rate in 393 
HFrEF patients with AF may involve a trade-off between symptom control and risk of death 394 
and hospitalization. Of course, our findings are observational in nature and this complicated 395 
and important clinical question is yet to be addressed in an adequate randomized clinical trial 396 
of rate control targets in patients with HFrEF and AF. Indeed, the resultant lack of evidence 397 
is reflected in the discrepancy between US guidance which advocates a target resting 398 
ventricular rate <80 bpm ,the European guidelines for AF which suggest a target of <110 399 
bpm based on the RACE-II trial, although the few patients in that trial with HF 400 
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predominantly had HFpEF, and the European guidelines for HF which suggest that a target of 401 
60-100bpm in patients with AF and HF may be preferable.23,30–32  402 
 403 
STRENGTHS AND LIMITATIONS 404 
The main strength of this study is its size, global nature and high levels of contemporary 405 
therapy, allowing generalisation of the results to a large proportion of HFrEF patients similar 406 
to those included in these trials. All study outcomes in both trials were adjudicated by the 407 
same clinical endpoint committee. The use of ECG reported heart rate negates issues with 408 
reliability in the manual recording of ventricular rate in AF. Additionally, the number of 409 
patients with missing data for NT-proBNP was small allowing for multivariable-adjusted 410 
models in almost the entire cohort after imputation for the 593 patients with missing data 411 
from the ATMOSPHERE trial (no imputation was performed for the 12 patients with missing 412 
NT-proBNP data from PARADIGM-HF). Our study also has limitations. It is a retrospective 413 
analysis and we have only accounted for heart rate and the presence or not of AF at baseline 414 
ECG recording. Our analysis does not account for the development of, or paroxysms of AF 415 
during the study. The analysis examining the associations between temporal changes in heart 416 
rate and outcomes do not account for changes in rate-limiting drug use or dose which may 417 
affect heart rate. The number of patients with very high or very low heart-rates were small. 418 
We have made efforts to adjust for differences in baseline characteristics between patients 419 
with AF and sinus rhythm and across heart rate tertiles. Despite this, as is inherent in any 420 
analysis of this nature, the risk of residual confounding remains high and our findings should 421 
be interpreted in context of this.33,34 Our results do not extend to those patients who were not 422 





In patients with HFrEF, an elevated heart rate in sinus rhythm was an independent predictor 427 
of both fatal and non-fatal adverse cardiovascular outcomes, even after adjustment for 428 
natriuretic peptide levels. Higher heart rate had a stronger relationship with death from pump 429 
failure than for sudden death. There was no relationship between heart rate and outcomes in 430 
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Table 1: Risk of outcomes with baseline heart rate as a continuous variable (per 10bpm 
increase) 
 
Table 2: Association between change in ECG recorded heart rate from baseline to 12 months 
and outcomes  
 






















Figure 1: Kaplan-Meier survival analysis according to baseline heart rate and rhythm 
 
Legend: Event curves for outcomes according to baseline heart rhythm and heart rate tertiles 
(tertile 1 lowest/tertile 3 highest). SR = sinus rhythm; AF = atrial fibrillation. 
 
Figure 2: Forest plot of relationship between baseline heart rate and outcomes by baseline 
heart rhythm 
 
Legend: Hazard ratios (HRs) of outcomes according to heart rhythm (AF or sinus rhythm) using each 
groups tertile 1 as reference. HRs with 95% confidence intervals were calculated using Cox models 
adjusted for same variables as detailed in Table 1. The p values are for interaction between AF and 
sinus rhythm with heart rate considered as a continuous variable. Abbreviations as per figure 2 
 
Figure 3:  Relationship between baseline heart rate modelled as a continuous variable and 
outcomes 
 
Legend: Hazard ratio for the effect of baseline heart rate on outcomes relative to a baseline 
heart rate of 80 beats per minute. Solid line represents the point estimates with dashed lines 
representing the 95% confidence intervals. Cox model adjusted for same variables as detailed 
in Table 2. SR = sinus rhythm; AF = atrial fibrillation. 
 31 
Table 1: Risk of outcomes with baseline heart rate as a continuous variable (per 10bpm increase) 
 
 Sinus rhythm (n=10,113) Atrial fibrillation (n=3449)  
 Unadjusted HR 
(95% CI) 
p value Adjusted HR 
(95% CI) 
p value Unadjusted HR 
(95% CI) 
p value Adjusted HR 
(95% CI) 
p value p value for 
interaction 
CV death or HF hospitalization 1.18 (1.15-1.21) <0.001 1.12 (1.09-1.16) <0.001    1.00 (0.97-1.04) 0.950 1.01 (0.98-1.05) 0.493 <0.001 
HF hospitalization 1.18 (1.14-1.22) <0.001 1.13 (1.09-1.18) <0.001 1.00 (0.95-1.05) 0.949 1.02 (0.97-1.07) 0.530 <0.001 
CV death 1.19 (1.15-1.23) <0.001 1.11 (1.07-1.15) <0.001 0.97 (0.93-1.02) 0.213 0.99 (0.95-1.04) 0.688  <0.001 
Pump failure death 1.25 (1.17-1.33) <0.001 1.17 (1.09-1.26) <0.001 0.89 (0.81-0.98) 0.014 0.94 (0.85-1.04) 0.222 <0.001 
Sudden death 1.18 (1.12-1.24) <0.001 1.07 (1.02-1.13) 0.011 0.98 (0.92-1.05) 0.545 0.97 (0.91-1.04) 0.444 0.032 
All-cause death 1.17 (1.14-1.21) <0.001 1.12 (1.08-1.15) <0.001 1.00 (0.96-1.04) 0.832 1.02 (0.98-1.06) 0.284 <0.001 
 
Cox model adjusted for age, sex, region, race, NYHA functional class, ejection fraction, systolic blood pressure, eGFR, diabetes, BMI, time since HF diagnosis, history of HF 
hospitalization, history of myocardial infarction, history of stroke, log NT-proBNP, treatment with betablocker, treatment with digoxin, treatment with amiodarone and 
randomized treatment (enalapril, sacubitril/valsartan, aliskiren, or combination).  











Table 2: Association between change in ECG recorded heart rate from baseline to 12 months and outcomes 
 Sinus Rhythm (n=7756) Atrial fibrillation (n=2504) 
 Event rate (95% C.I.) Adjusted HR (95% C.I.) Event rate (95% C.I.) Adjusted HR (95% C.I.) 
CV death or HF hospitalization 
≤ -10 bpm 10.0 (8.7-11.4) 0.74 (0.63-0.87); p<0.001 10.9 (9.1-13.1) 0.83 (0.65-1.07); p=0.147 
< +/-10 bpm 9.9 (9.2-10.5) 1.00 (Referent) 11.8 (10.4-13.4) 1.00 (Referent) 
≥ +10 bpm 14.5 (13.1-16.0) 1.52 (1.34-1.72); p<0.001 14.5 (12.4-16.9) 1.31 (1.07-1.61); p=0.010 
CV death      
≤ -10 bpm 6.4 (5.4-7.5) 0.82 (0.67-1.01); p=0.060 6.8 (5.4-8.5) 0.81 (0.60-1.10); p=0.173 
< +/-10 bpm 5.7 (5.3-6.2) 1.00 (Referent) 7.6 (6.5-8.8) 1.00 (Referent) 
≥ +10 bpm 8.6 (7.6-9.8) 1.53 (1.31-1.80); p=<0.001 8.7 (7.2-10.5) 1.23 (0.96-1.58); p=0.103 
HF hospitalization     
≤ -10 bpm 5.2 (4.3-6.3) 0.69 (0.55-0.87); p=0.001 6.3 (4.9-8.0) 1.01 (0.73-1.39); p=0.972 
< +/-10 bpm 5.6 (5.1-6.1) 1.00 (Referent) 6.3 (5.4-7.5) 1.00 (Referent) 
≥ +10 bpm 8.4 (7.4-9.7) 1.60 (1.36-1.90); p<0.001 9.1 (7.5-11.1) 1.55 (1.18-2.02); p=0.001 
Pump failure death     
≤ -10 bpm 1.4 (1.0-2.0) 0.73 (0.48-1.13); p=0.163 1.0 (0.6-1.8) 0.55 (0.27-1.18); p=0.110 
< +/-10 bpm 1.4 (1.2-1.7) 1.00 (Referent) 1.9 (1.4-2.5) 1.00 (Referent) 
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Event rates presented as per 100 patient years.  
Cox model adjusted for same variables as detailed in Table 1 and baseline heart rate. 















≥ +10 bpm 1.9 (1.5-2.5) 1.51 (1.08-2.10); p=0.015 3.5 (2.6-4.8) 2.26 (1.46-3.52); p<0.001 
Sudden cardiac death     
≤ -10 bpm 2.9 (2.3-3.7) 0.82 (0.61-1.12); p=0.218 3.1 (2.2-4.3) 0.91 (0.57-1.45); p=0.681 
< +/-10 bpm 2.5 (2.2-2.9) 1.00 (Referent) 2.9 (2.3-3.7) 1.00 (Referent) 
≥ +10 bpm 3.2 (2.6-3.9) 1.20 (0.94-1.55); p=0.150 3.0 (2.1-4.1) 1.01 (0.66-1.54); p=0.969 
All-cause death     
≤ -10 bpm 7.7 (6.6-8.9) 0.83 (0.69-1.00); p=0.050 7.8 (6.3-9.6) 0.75 (0.56-0.99); p=0.040 
< +/-10 bpm 6.9 (6.4-7.5) 1.00 (Referent) 9.1 (8.0-10.5) 1.00 (Referent) 





Table 3: Association between change in heart rate at 12 months and change in KCCQ and NT-proBNP 
 
 
 Sinus Rhythm Atrial Fibrillation 
     Change in heart rate ≤ -10 bpm 
(n=1274) 
< +/-10 bpm 
(n=4943) 




≤ -10 bpm 
(n=611) 
< +/-10 bpm 
(n=1217) 
≥ +10 bpm 
(n=676) 
p for trend 
Increase in KCCQ at 12 months 














Decrease in KCCQ at 12 months 














Mean (±SD) change in NT-
proBNP at 12 months (pg/ml)* 
-4142271 +592294 +4242754 p<0.001 -1212279 -401412 2592327 p=0.034 
 
*Data available for 3835 (84%) patients from ATMOSPHERE only 
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Event curves for outcomes according to baseline heart rhythm and heart rate tertiles (tertile 1 lowest/tertile 3 highest). SR = sinus rhythm; AF = atrial fibrillation. 
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Hazard ratios (HRs) of outcomes according to heart rhythm (AF or sinus rhythm) using each groups 
tertile 1 as reference. HRs with 95% confidence intervals were calculated using Cox models adjusted 
for same variables as detailed in Table 1. The p values are for interaction between AF and sinus 
rhythm with heart rate considered as a continuous variable. Abbreviations as per figure 2.
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Hazard ratio for the effect of baseline heart rate on outcomes relative to a baseline heart rate of 80 beats per minute. Solid line represents the point 
estimates with dashed lines representing the 95% confidence intervals. Cox model adjusted for same variables as detailed in Table 1 
SR = sinus rhythm; AF = atrial fibrillation.
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